LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | JW-7-24-1 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 4183 | 5013 | 0.8343 | 0.7756 |
MDA-MB-231 | Lapatinib | 0.37 | uM | LJP6 | 72 | hr | 1311 | 4748 | 5013 | 0.9470 | 0.9283 |
MDA-MB-231 | LDN-193189 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4623 | 5013 | 0.9222 | 0.8946 |
MDA-MB-231 | Linifanib | 0.37 | uM | LJP6 | 72 | hr | 1311 | 5129 | 5013 | 1.0230 | 1.0312 |
MDA-MB-231 | Linsitinib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4864 | 5013 | 0.9702 | 0.9596 |
MDA-MB-231 | Mitoxantrone | 0.37 | uM | LJP5 | 72 | hr | 1311 | 1009 | 5013 | 0.2014 | -0.0816 |
MDA-MB-231 | Mitoxantrone | 0.37 | uM | LJP6 | 72 | hr | 1311 | 992 | 5013 | 0.1979 | -0.0863 |
MDA-MB-231 | MK2206 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 4166 | 5013 | 0.8310 | 0.7711 |
MDA-MB-231 | Neratinib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4362 | 5013 | 0.8701 | 0.8241 |
MDA-MB-231 | Nilotinib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4736 | 5013 | 0.9446 | 0.9250 |
MDA-MB-231 | Nintedanib | 0.37 | uM | LJP6 | 72 | hr | 1311 | 4883 | 5013 | 0.9741 | 0.9649 |
MDA-MB-231 | NU7441 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4539 | 5013 | 0.9054 | 0.8719 |
MDA-MB-231 | Dactolisib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 2036 | 5013 | 0.4062 | 0.1958 |
MDA-MB-231 | NVP-TAE684 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 3917 | 5013 | 0.7813 | 0.7038 |
MDA-MB-231 | Palbociclib | 0.37 | uM | LJP6 | 72 | hr | 1311 | 2996 | 5013 | 0.5976 | 0.4550 |
MDA-MB-231 | PD0325901 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 2182 | 5013 | 0.4354 | 0.2353 |
MDA-MB-231 | PD0325901 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 2062 | 5013 | 0.4113 | 0.2027 |
MDA-MB-231 | PD173074 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 5192 | 5013 | 1.0357 | 1.0484 |
MDA-MB-231 | PD184352 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4016 | 5013 | 0.8011 | 0.7306 |
MDA-MB-231 | Pelitinib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4647 | 5013 | 0.9270 | 0.9012 |
MDA-MB-231 | PF431396 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 3285 | 5013 | 0.6552 | 0.5331 |
MDA-MB-231 | PF477736 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4546 | 5013 | 0.9068 | 0.8737 |
MDA-MB-231 | PF562271 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 3973 | 5013 | 0.7925 | 0.7189 |
MDA-MB-231 | PHA-665752 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 5000 | 5013 | 0.9974 | 0.9964 |
MDA-MB-231 | PHA-793887 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 1482 | 5013 | 0.2957 | 0.0462 |